



Innovations that work.™

ACN 109 200 900

ASX ANNOUNCEMENT

30 October 2026

SEPTEMBER 2026 QUARTERLY ACTIVITIES REPORT

Eden Innovations Ltd (ASX:EDE) (“Eden” or “the Company”) is pleased to provide the following activities report for the quarter ended 30 September 2026.

HIGHLIGHTS

Strong US Revenue Growth and Plant Expansion:

- Eden US sales for the quarter were US\$381,612 (A\$549,521), more than two and a half times Q1 FY26. OptiBlend® sales of US\$259,863 were up 247%, and EdenCrete® product sales of US\$121,749 were up 60%, with EdenCrete®Pz7 sales up almost four-fold.
- 6 new EdenCrete®Pz7 bulk storage and dispensing installations completed at ready-mix concrete plants in Colorado, Texas and Minnesota, with two more scheduled for October 2026, bringing the total to 32 plants in the USA, Canada and Ecuador.
- Long term trial success with the Amrize group resulted in the first EdenCrete®Pz7 installations in Texas and Minnesota, with further plant expansion with Amrize in Canada.
- First OptiBlend® export sale to Brazil; further quotes submitted in Brazil, Mexico and Bolivia and for a US Army Corps of Engineers project (approx. US\$249k).

Positive Indian Government EdenCrete® Trials:

- The final CRRRI study report (announced 22 July 2026) confirmed significant increases in abrasion resistance, compressive and flexural strength, and reduced drying-shrinkage, compared with the control mixes. Eden India intends to explore with CRRRI accelerated field trials for new highways and white topping highway repairs.
- Eden India continues to target the ready-mix concrete markets in Mumbai and Delhi.

OptiBlend® US Momentum: Nine (9) OptiBlend® orders worth US\$259,863 received during the quarter, up 247% on Q1 FY26; quotes of approx. US\$916k (16 quotes) submitted in the USA, plus further quotes in Mexico and Bolivia.

Debt Free Status Achieved: Following shareholder approval at the General Meeting held on 24 July 2026, shares were issued to settle all remaining shareholder loans and accrued director fees, completing the Company’s balance sheet reconstruction.

EdenCrete® Presented at International CO₂ Reduction Symposium: Eden’s Chief Scientist and Managing Director, Dr Allan Godsk Larsen, was an invited speaker at the Aarhus Power-to-X Symposium 2026 in Denmark, presenting Eden’s CNT technology and EdenCrete®.

Outlook: Eden ended Q1 FY27 debt free, with \$4.3 million cash at bank at 30 September 2026, and Eden US is targeting continued year on year revenue growth in FY27, subject to market conditions.

SALES AND ACTIVITIES DURING Q1 FY27


Eden Innovations Ltd (ASX: EDE) is pleased to report a strong start to FY2027. Sales achieved by its wholly owned US subsidiary, Eden Innovations LLC (“Eden US”), for the quarter were more than two and a half times the total sales for the corresponding quarter of the prior year, with strong growth being seen in both EdenCrete® and OptiBlend® sales, and six new EdenCrete®Pz7 bulk storage and dispensing installations were completed at ready-mix concrete plants across the USA.

EdenCrete® Products Highlights

Ready Mix Concrete Plant Growth and North American Expansion

During the quarter, Eden US installed 6 new EdenCrete®Pz7 bulk storage tank and dispensing equipment installations at ready-mix concrete (“RMC”) plants in the USA, being 3 in Colorado, 2 in Texas and 1 in Minnesota, continuing the steady expansion since 2024. There are two more installations scheduled to be installed in October 2026.

As requested by Amrize in July 2026, Eden US installed EdenCrete®Pz7 bulk storage and automated dispensing systems at a double-plant site in Texas and at a further plant in Minnesota (extending Eden’s US footprint into two new states), and at a second plant in the greater Toronto area, Canada, in response to growing demand for EdenCrete®Pz7-enriched concrete mixes in the Canadian market.



This brings the number of plants with bulk installations for all EdenCrete® products in the USA and Canada to 23 (including the 2 pending installations). Ecuador has 9 installations in total, making a grand total of 32 plants, with numerous other plants in many locations undertaking trials or planning trials.

Each new installation is accompanied by an order for a small starter volume of EdenCrete®Pz7, typically generating US\$6,000 – US\$10,000 in sales. Of greater significance is the ongoing consumption once a plant is fully integrated. Based upon sales growth of the 9 plants in Ecuador observed since 2024, it is anticipated that each plant will progressively build its purchases of EdenCrete®Pz7 on average to somewhere in the vicinity of US\$40,000 to US\$80,000 per year per plant. FY27 Q2 figures in the chart above include the two installations scheduled for October 2026.

The growing number of RMC plants with EdenCrete® Pz7 dispensing systems is increasingly reflected in projects where the product is specified in the concrete mix design. In Colorado, for example, current projects using EdenCrete® Pz7 include a high-rise multi-use apartment development (24,000 cubic yards of concrete), town homes (16,000 cy), residences (4,500 cy) and a hospital (3,000 cy).

South America and International Markets

Eden US has been supplying EdenCrete® Pz7 to enrich standard low-carbon concrete mixes at nine Holcim plants in Ecuador since 2024. Cumulative orders from Holcim Ecuador totalled US\$697,870 at the end of the quarter. Subsequent to quarter end, Eden received a further order of US\$334,110 (see ASX announcement of 29 October 2026), taking cumulative orders from this customer past US\$1 million.

Given its strong foothold in the region, Eden is considering placing greater emphasis on the South American concrete market, including evaluating opportunities for EdenCrete® Pz7 in further countries across South and Central America.

Eden US Revenue – Strong Q1 FY27 Growth

Total sales achieved by Eden US for the quarter were US\$381,612 (A\$549,521*), being more than two and a half times the total sales for the corresponding quarter of the prior year (Q1 FY26: US\$151,237), with strong growth being seen in both EdenCrete® and OptiBlend® sales.

Product	Country	Q1 FY26 US\$	Q1 FY27 US\$	Q1 FY27 A\$*	Change (US\$)
EdenCrete®Pz7	USA	3,978	59,770	86,069	+55,792
EdenCrete®Pz7	Canada	16,000	16,000	23,040	–
EdenCrete®	USA	56,298	45,979	66,210	-10,319
Total EdenCrete® products		76,275	121,749	175,319	+45,474 (+60%)
OptiBlend®	USA	74,961	259,863	374,203	+184,902 (+247%)
Total Eden US revenue		151,237	381,612	549,521	+230,376 (+152%)

(*Converted at A\$1.44 per US\$1.00. Figures are unaudited management figures for Eden US.)

Total sales of all EdenCrete® products during the quarter of US\$121,749 (A\$175,319) were 60% higher than Q1 FY26. EdenCrete®Pz7 sales increased almost four-fold to US\$75,770 (A\$109,109), reflecting starter volume orders for the newly installed plants and replenishment orders from the growing number of RMC plants in the USA and Canada that already have EdenCrete®Pz7 bulk storage and dispensing installations.

OptiBlend® sales of US\$259,863 (A\$374,203) were 247% higher than Q1 FY26, comprising OptiBlend® kit sales and installation services to genset packagers, drilling contractors and other customers in Texas, Louisiana and Florida, including a maiden export sale to Brazil.

EdenShield® Division Update

EdenShield®, Eden's dedicated defence, military and critical infrastructure division, continued business development activities during the quarter in Australia, led by Ms Julie Bown (Strategic Advisor – Defence). This work included engagement with Defence and government stakeholders, alignment of Eden's technologies to operational requirements, and progression of commercialisation pathways for EdenShield® products. Eden is reviewing the geographic focus of its EdenShield® activities to determine which markets, including Australia, offer the strongest commercial prospects for the division.

Aarhus Power-to-X Symposium

As announced on 9 July 2026, Eden's Chief Scientist and Managing Director, Dr Allan Godsk Larsen, was an invited speaker at the Aarhus Power-to-X Symposium 2026 in Denmark, where he presented Eden's carbon nanotube (CNT) technology and EdenCrete® in a session dedicated to "CO₂-to-Building Materials" and reducing the CO₂ footprint of construction. The symposium, organised by Aarhus University and leading Danish research institutions, brought together two hundred industry leaders and researchers, primarily from Europe, and the invitation places Eden alongside world-leading universities, technology companies and government agencies working to advance net-zero solutions.

Eden India – Positive Indian Government EdenCrete® Trials

As announced on 22 July 2026, the EdenCrete®Pz7 trials in Indian concrete mixes conducted by the Central Road Research Institute (CRRI), an Indian Government agency, in the CRRI laboratory in Delhi, produced highly encouraging results, as outlined in the final study report received by Eden on 21 July 2026.

Compared with the control mixes, the EdenCrete®Pz7 enriched concrete mixes significantly increased abrasion resistance (by up to 28%), compressive strength (up to 19%) and flexural strength (up to 14%), and reduced drying-shrinkage by up to 25%, across the two grades trialled – an M40 pavement quality concrete used for new highways and an M60 grade concrete used for bridge overlay and "white topping" repair of worn concrete pavement.

The strength buffer generated by EdenCrete®Pz7 enables replacement of a meaningful percentage of expensive Ordinary Portland Cement and micro silica with much cheaper supplementary cementitious materials such as fly ash or slag, resulting in stronger, cheaper concrete with a significantly lower CO₂ footprint. Further trials with CRRI are scheduled. Eden India intends to explore with CRRI ways to accelerate appropriate field trials of EdenCrete® enriched concrete for new highways and white topping highway repairs.

Eden India is also targeting ready-mix concrete producers in Delhi and Mumbai, where trials are continuing based on the positive results and feedback from the parties involved.

OptiBlend® Highlights

Overview

OptiBlend® is Eden's patented retrofit dual-fuel technology that allows conventional diesel engines to operate primarily on natural gas — up to a 65% natural gas / 35% diesel mix — without modification to the engine or existing diesel fuel system. This reduces fuel costs, lowers CO₂ and diesel particulate emissions, and extends backup generator run-time by up to 300%.

The technology is attracting growing interest from US data centre operators seeking to reduce operating costs and emissions while improving energy security.

OptiBlend® addresses a clear operational need for backup power operators — lower fuel costs, reduced emissions, and a dramatic increase in generator runtime — without requiring any modification to existing engines or diesel fuel infrastructure.

US Sales & Pipeline

During the quarter, Eden US received nine (9) OptiBlend® orders worth US\$259,863 (A\$374,203), an increase of 247% on Q1 FY26 (US\$74,961). The orders comprised OptiBlend® kit sales and installation services to genset packagers, drilling contractors and other customers in Texas, Louisiana and Florida. The first OptiBlend® unit was also shipped to Brazil (approx. US\$26k), with further opportunities in Brazil being pursued, and installation of two further OptiBlend® kits, with a value of approx. US\$110k, is planned for October 2026.

Quotation activity remains strong. Quotes submitted include approx. US\$916,242 across 16 quotes in the USA, US\$108,000 (2 quotes) in Mexico and US\$43,087 (1 quote) in Bolivia.

Further, an OptiBlend® quote of approx. US\$249k has been submitted (with a generator supplier) for a US Army Corps of Engineers (ACE) project that is currently in the bidding process. Eden India is also currently pursuing significant OptiBlend® opportunities in India, the Middle East and Africa.

Corporate Activities

Debt Free Status Achieved – General Meeting Results

At the General Meeting of the Company held on 24 July 2026, all resolutions were passed by a poll without amendment, including ratification of the \$4.05 million institution-led placement completed in the June quarter and approval of the issue of shares in lieu of outstanding loans and accrued director fees.

Following that approval, the Company issued shares to settle all outstanding loans from Arkenstone Pty Ltd and March Bells Pty Ltd and accrued director fees totalling \$1,839,141 in aggregate, at the same price as the earlier convertible loan settled in February 2026, completing the Company's move to debt-free status. A small residual balance on these loans remains to be repaid in cash.

Funding

At 30 September 2026, the Company had \$4.3 million cash at bank, and remains free of third-party debt.

Management

The hiring of additional US business development staff is being finalised, to continue to drive EdenCrete® and OptiBlend® sales.

Group Outlook and Priorities

With Eden's recapitalisation complete and the Company now debt free, the focus for FY2027 is on converting the growing number of EdenCrete® plant installations, the trial pipeline and the active OptiBlend® quotation pipeline into growing recurring revenues.

With Q1 FY27 US sales more than two and a half times those of the prior corresponding period, Eden US has made an encouraging start to FY27. Whilst quarterly sales will continue to fluctuate, Eden US is targeting continued year on year revenue growth in FY27, subject to market conditions.

Key priorities for FY2027 include:

- Converting the positive Indian trial results with CRRI, ready mix concrete producers and high-rise developers into field trials and commercial sales;
- Scaling EdenCrete® Pz7 sales across the Amrize, Quikrete, and Holcim ready mix plant networks in the Americas, including the new installations in Texas, Minnesota and Toronto;
- Securing initial commercial engagements and pilot project opportunities for EdenShield®;
- Expanding OptiBlend® order flow from US data centre operators, drilling contractors and genset packagers, and converting the active US and Latin American quotation pipelines;
- Advancing carbon nanotube concrete R&D for innovative new applications;
- Progressing EdenCrete® trials and partnerships; and
- Continuing to advance towards the Group's target to reach positive operating cash flow.

Description of payments to related parties of the entity and their associates (LR 5.3.5)

The Company paid \$304k to related parties during the quarter, comprising \$132k to Dr Allan Larsen for Managing Director services and \$172k for Executive Chair and Non-executive director fees. Payments include a one-off amount of accrued superannuation of \$135k on director fees for approximately 3 years that were settled through the issue of shares approved at the General Meeting held on 24 July 2026.

ENDS



Gregory H Solomon

Executive Chairman

This report was authorised by the Board of the Company.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of the Company are, or may be, forward looking statements. Such statements relate to future events and expectations and as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors. The past performance of the Company is no guarantee of future performance.

None of the Company's directors, officers, employees, agents or contractors makes any representation or warranty (either express or implied) as to the accuracy or likelihood of fulfilment of any forward-looking statement, or any events or results expressed or implied in any forward-looking statement, except to the extent required by law. You are cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statements in this announcement reflect views held only as at the date of this announcement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Eden Innovations Ltd

ABN

58 109 200 900

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (3 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		979	979
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(115)	(115)
(c) advertising and marketing		-	-
(d) leased assets		-	-
(e) staff costs		(1,059)	(1,059)
(f) administration and corporate costs		(716)	(716)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		19	19
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes paid (India)		-	-
1.7 Government grants and tax incentives		-	-
1.8 Other (provide details if material)		-	-
1.9 Net cash from / (used in) operating activities		(892)	(892)
2. Cash flows from investing activities			
2.1 Payments to acquire or for:		-	-
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		(10)	(10)
(d) investments		-	-
(e) intellectual property		-	-
(f) other non-current assets		-	-

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(10)	(10)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	2	2
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	2	2

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	5,178	5,178
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(892)	(892)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(10)	(10)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2	2
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	4,278	4,278

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current Quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	3,263	4,176
5.2 Call deposits	1,014	1,002
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,278	5,178

6. Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	304
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>	
Director fees, including superannuation, paid to the managing director, non-executive director and executive chairman .	

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at Quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	56	56
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	56	56
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> At call, unsecured loans from Arkenstone Pty Ltd and March Bells Pty Ltd, entities associated with directors. Residual balance remaining after settlement of \$1,185,000 of the loans through the issue of shares approved at the General Meeting held on 24 July 2026, to be repaid in cash. Interest at 9.97% pa. </div>		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(892)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,278
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,278
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.8
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A	
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: Brett Tucker, Company Secretary
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.